More recently, treatment of a HER2+ breast cancer cell line tumor in a humanized mouse model with a trispecific antibody to HER2, CD3, and CD28 and adoptive transfer of CD4+ T cells demonstrated regression of cancer (33). This evidence concerns the gene ERBB2 and cancer.